Efficacy and Safety of Switching From Pegylated Interferon/Ribavirin (PR) to Direct-acting Antiviral Agents (DAAs) for Chinese With CHC Genotype 1b Infection (SWITCH-1)
Phase of Trial: Phase II
Latest Information Update: 20 Jan 2017
At a glance
- Drugs Asunaprevir (Primary) ; Ledipasvir/sofosbuvir (Primary) ; Simeprevir (Primary) ; Interferon alpha-2a; Ribavirin
- Indications Hepatitis C
- Focus Adverse reactions; Therapeutic Use
- Acronyms SWITCH-1
- 15 Jan 2017 Planned End Date changed from 1 Dec 2016 to 1 Dec 2017.
- 15 Jan 2017 Planned primary completion date changed from 1 Dec 2016 to 1 Dec 2017.
- 18 Aug 2016 Planned End Date changed from 1 Sep 2016 to 1 Dec 2016.